Home › Compound Library › Tesamorelin
Growth hormone axis
Tesamorelin: The Approved GHRH Analog, and What Its Trials Actually Showed
The short answer
Tesamorelin is the one compound in this family that cleared the full regulatory path. Sold as Egrifta, it is FDA approved to reduce excess abdominal fat in people with HIV-associated lipodystrophy, on the strength of Phase 3 trials. Everything else it gets discussed for, including liver fat and memory, is research rather than approved use.
Questions people ask about Tesamorelin
Tesamorelin at a glance
| Also called | Egrifta, Egrifta SV, Egrifta WR; TH9507 |
|---|---|
| What it is | Stabilised synthetic analog of growth hormone-releasing hormone (GHRH) |
| Acts on | The GHRH receptor in the anterior pituitary |
| Main system | Growth hormone axis; studied for visceral fat and liver fat |
| Evidence level | Phase 3 trials in its approved population; smaller trials elsewhere |
| FDA status (Sept 2026) | Approved, prescription only, for HIV-associated lipodystrophy. Not approved for weight loss, ageing or performance |
| In sport | Prohibited at all times (WADA S2.2.4, GHRH analogs, named) |
What is tesamorelin?
Tesamorelin is GHRH with a chemical modification that keeps it intact long enough to do its job. Like sermorelin and CJC-1295, it tells the pituitary to release growth hormone rather than supplying the hormone directly.
The difference is the paperwork behind it. It went through Phase 3 trials, was approved by the FDA in 2010, and is prescribed under the name Egrifta for a specific problem: the build-up of deep abdominal fat that can occur in people with HIV on long-term antiretroviral therapy.
Targeted Peptide Systems (pp. 201–203) and Metabolic Precision (pp. 128–130) both treat it as the reference point of the GHRH class: the compound whose effects are documented rather than inferred.
How does tesamorelin work?
It binds the GHRH receptor, the pituitary releases growth hormone in its normal pulsing pattern, and the liver produces IGF-1 in response.
The reason this shows up as visceral fat loss specifically is that deep abdominal fat is unusually responsive to growth hormone’s fat-releasing signal. Growth hormone increases the breakdown of stored fat, and visceral tissue gives it up faster than fat under the skin.
Metabolic Precision (pp. 69–73) explains why that matters beyond appearance: visceral fat suppresses growth hormone release on its own, so reducing it partly repairs the axis that was being suppressed.
What does the research show?
The pivotal trial. Falutz and colleagues, 2007, in the New England Journal of Medicine: in people with HIV-associated abdominal fat accumulation, tesamorelin reduced visceral fat significantly compared with placebo, with triglycerides improving alongside (reference 1).
The longer view. A 2008 follow-up in AIDS extended treatment to a year and reported that the reduction held while treatment continued, with the effect reversing after it stopped (reference 2). This is the part worth remembering: it is a treatment, not a cure.
Beyond the label. Two research directions come up repeatedly. Liver fat, where tesamorelin has been studied in fatty liver disease in people with HIV; and cognition, where a 2012 trial in Archives of Neurology found that GHRH administration improved some cognitive measures in older adults with and without mild cognitive impairment (reference 3). Neither is an approved use, and the cognition finding needs replication at scale.
Side effects and cautions
The trials reported injection-site reactions, joint pain, swelling in the limbs, muscle aches and tingling in the hands. Blood sugar can drift upward because growth hormone reduces insulin sensitivity, so glucose and HbA1c are monitored during treatment (reference 5).
It is contraindicated in pregnancy, in active malignancy, and in people with disruption of the pituitary axis from surgery, radiation or trauma.
Because it is an approved medicine, there is a real prescribing framework here: a defined population, monitoring, and a manufacturer. Material bought outside that framework carries none of it.
Is tesamorelin FDA approved?
Yes, for one thing. Tesamorelin is approved as a prescription medicine to reduce excess abdominal fat in adults with HIV-associated lipodystrophy. It is not approved for general weight loss, for ageing, for muscle gain or for cognitive performance.
That distinction matters more than usual here, because “FDA approved” gets used in marketing to imply approval for whatever is being sold.
Banned in sport. WADA names tesamorelin among prohibited GHRH analogs, at all times (reference 6).
Tesamorelin vs ipamorelin, sermorelin and CJC-1295
- vs ipamorelin: different receptor. Ipamorelin uses the ghrelin receptor; tesamorelin is a GHRH analog. The bigger difference is evidence: tesamorelin has Phase 3 data and an approval, ipamorelin has neither. See our ipamorelin profile.
- vs sermorelin: same class, same receptor. Tesamorelin is the stabilised, trialled and approved version.
- vs CJC-1295: same class again, and they should not be combined. CJC-1295’s long-acting DAC form keeps growth hormone raised for days; tesamorelin is dosed to work with the daily rhythm. See our CJC-1295 profile.
- vs tirzepatide and the GLP-1 class: a different job entirely. Those act on appetite and insulin; tesamorelin acts on the growth hormone axis. Metabolic Precision (pp. 223–225) puts metabolic correction first and growth hormone support second, not the reverse.
Risk, benefit, and the conversation this page is for
How to weigh it. Some research peptides have a quiet toxicology record, or an unfinished efficacy record. tesamorelin is a different case: on its mechanism it genuinely moves physiology, in this case growth hormone and IGF-1, and that is the reason to weigh it with due diligence rather than enthusiasm. Monitoring is paramount here, and the markers that matter are glucose and HbA1c, which is exactly why the approved product is prescribed with monitoring.
The regulatory picture is moving, selectively. In July 2026 an FDA advisory committee recommended six peptides, BPC-157, TB-500, KPV, MOTS-c, Epitalon and Semax, for the list of bulk substances compounding pharmacies may use. Tesamorelin did not need the committee’s recommendation. It is an approved prescription medicine, which is the far end of the same spectrum this library covers. Reading those decisions one at a time is more useful than treating every compound outside the approved list as equivalent.
Why the class is taken seriously. This is the page in the library with the least to argue about. The trials were run, the drug was approved, and the questions that remain are about who it suits rather than whether it works. That makes the due diligence a shared job with a prescriber rather than a solo one, which is most of what an approval changes in practice.
Which is the point of the series. Nothing here is a recommendation to use tesamorelin. People misuse approved medicines and unapproved compounds alike, and that is neither the purpose nor the intent of this page. The point is a better conversation than the internet usually allows: with a clinician who knows your history, your labs and everything else you take, and who can help build a plan that fits you.
Tesamorelin: frequently asked questions
What is tesamorelin used for?
It is FDA approved to reduce excess abdominal fat in adults with HIV-associated lipodystrophy. Other uses, including liver fat and cognition, are research rather than approved indications.
Is tesamorelin FDA approved?
Yes, as Egrifta, for that one population. It is not approved for weight loss, ageing, muscle gain or performance.
Tesamorelin vs ipamorelin: which is better?
They are not the same class and the evidence is not comparable. Tesamorelin is an approved medicine with Phase 3 data; ipamorelin is an unapproved research compound acting on a different receptor.
Tesamorelin vs sermorelin: what is the difference?
Both are GHRH analogs. Tesamorelin is the stabilised version that went through clinical trials and approval; sermorelin is shorter-acting and is not approved for this use.
Does tesamorelin reduce belly fat?
In its trial population, yes: it significantly reduced visceral abdominal fat compared with placebo (reference 1). The effect reversed after treatment stopped (reference 2). The trials were run in that population, so what it does outside it is the open question.
Does tesamorelin help with memory?
A 2012 trial found that GHRH administration improved some measures of cognition in older adults with and without mild cognitive impairment (reference 3). It is not an approved treatment for memory, and the finding needs larger studies.
What are tesamorelin’s side effects?
Injection-site reactions, joint pain, limb swelling, muscle aches, tingling in the hands, and rising blood sugar in some people. It is not for use in pregnancy or active cancer.
Is tesamorelin banned in sport?
Yes. It is named on WADA’s prohibited list among growth hormone releasing factors, banned at all times (reference 6).
Where Tesamorelin appears in our books
This page is the plain-language overview. The books go further: mechanism detail, evidence tiers, how Tesamorelin fits a full protocol, and the cautions that go with it. Page numbers refer to the print editions.
Related compounds
See how Tesamorelin fits a protocol
The free Protocol Builder maps the pathways a compound works on and shows what complements it for your goal, built from the same database as this library.
Open the Protocol BuilderSee the book seriesReferences
- Falutz J, Allas S, Blot K, et al. Metabolic effects of a growth hormone-releasing factor in patients with HIV. N Engl J Med. 2007;357(23):2359–2370. View sourceCited in Metabolic Precision (p. 354) and The Longevity Map (p. 198)
- Falutz J, Allas S, Mamputu JC, et al. Long-term safety and effects of tesamorelin, a growth hormone-releasing factor analogue, in HIV patients with abdominal fat accumulation. AIDS. 2008;22(14):1719–1728. View source
- Baker LD, Barsness SM, Borson S, et al. Effects of growth hormone-releasing hormone on cognitive function in adults with mild cognitive impairment and healthy older adults. Arch Neurol. 2012;69(11):1420–1429. View source
- National Community Pharmacists Association. FDA advisory committee nominates six peptides for pharmacies to compound. July 31, 2026. View source
- Møller N, Jørgensen JO. Effects of growth hormone on glucose, lipid, and protein metabolism in human subjects. Endocr Rev. 2009;30(2):152–177. View source
- World Anti-Doping Agency. The 2026 Prohibited List. View source
How this page is maintained. Regulatory status and trial results change. We review this page against current sources and update it as new information becomes available; the date at the top shows the last review.
Educational information only, not medical advice. Tesamorelin is discussed here for education. Nothing on this page is a recommendation to use it or a dosing guide. Talk to a qualified clinician before starting, stopping or combining any compound.